Cognizant Technology Solutions (CTSH) is on an innovation spree, leveraging AI all while undertaking share buybacks and receiving price target upgrades, notably the increment to $88.00 by Royal Bank of Canada. Despite Gross Margin contraction to a 10.2% which inevitably invokes bearish profitability narratives, CTS has performed well in its latest quarter as evidenced by its Q4 earnings beating estimates. Their partnership with Palantir is poised to impel AI-driven modernization in healthcare and enterprise operations. Strikingly, the company's share price surged following an astounding mixed Q4 results. Additional boost on its stock price came from CTS's strategic partnership with the Venbrook Group, which was announced recently. The company's three-year performance demonstrates an impressive 37% gain for investors. Their Q4 Earnings call showed promising outlook for 2026, projecting an adjusted EPS range $5.56 to $5.70, marginally above FactSet's estimate. CTS's future appears bright given its ambitious 2026 revenue forecast anywhere between $22.14B to $22.66B. In other news, newly formed alliances, its latest AI plan for drug discovery and new acquisitions provide compelling insights into CTS's revamped strategy and long-term vision.
Cognizant Technology Solutions CTSH News Analytics from Mon, 15 Sep 2025 07:00:00 GMT to Sat, 07 Feb 2026 12:12:44 GMT - Rating 6 - Innovation 7 - Information 9 - Rumor 8
